Gujarat Kidney And Super Speciality Appoints Secretarial & Internal Auditors for FY26
Gujarat Kidney And Super Speciality Limited appointed Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY26. The company reported Q2 FY26 standalone net profit of ₹2.30 crore and half-yearly profit of ₹6.20 crore. Consolidated Q2 FY26 net profit was ₹2.32 crore.
The appointment of auditors is a standard corporate governance practice. The financial results, while important, do not show extraordinary performance that would warrant a high impact. The impact is considered medium as it pertains to operational and financial health.
The announcement details routine management appointments and financial results, which are neutral in nature. There are no significant positive or negative developments.
Gujarat Kidney And Super Speciality Limited announced key management appointments following a Board meeting held on March 19, 2026. Mr. Dharmendra Bhaliya, a Practicing Company Secretary from Vadodara, has been appointed as the Secretarial Auditor for the Financial Year 2025-26.
Additionally, Mr. Siddharth Atulbhai Shah, a Chartered Accountant, has been appointed as the Internal Auditor for the same financial year. The Board also ratified and confirmed actions taken in a previous meeting held on February 14, 2026, resubmitting certain information with corrections.
The company also released its unaudited standalone financial results for the quarter and half-year ended September 30, 2025. Total Income for the quarter stood at ₹965.77 lacs, with a Profit After Tax of ₹230.12 lacs. For the half-year, Total Income was ₹2,110.91 lacs, and Profit After Tax was ₹620.10 lacs.
The consolidated financial results for the same period showed Total Income of ₹2,110.91 lacs for the quarter and ₹4,364.43 lacs for the half-year. Profit After Tax for the consolidated entity was ₹232.18 lacs for the quarter and ₹623.25 lacs for the half-year.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.